GeoVax Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 27, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 15, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $0 | $-0.31 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | During market hours | $852.28K | $-0.35 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | During market hours | $1.60M | $-0.45 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $2.79M | $-0.91 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | $301.00K | $-1.99 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 1, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | – | – | – |
Press releases
Announcements GeoVax Labs filed with the SEC
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
Other events · EX-99.1 to Form 8-K
GeoVax Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Announces $3 Million Private Placement Financing Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports First Quarter 2026 Financial Results and
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2025 Year-End Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
GeoVax Labs Announces $2.5 Million Registered Direct Offering
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $6 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2024 Year-End Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Labs Announces $4.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports Third Quarter 2024 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $5.0 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $8.5 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $3.1 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax to Raise Approximately $1.3 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2023 Year-End Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2023 Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2023 First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2022 Year-End Financial Results
Results of operations · EX-99.1 to Form 8-K
GeoVax Reports 2022 Third Quarter
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Gabrielle DeGravina - CG Capital
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
GeoVax Reports 2022 Second Quarter Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2022 Second Quarter Financial Results
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GeoVax Reports 2022 First Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
First Quarter 2022, Corporate Update Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
GeoVax Reports 2021 Year-End Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fourth Quarter 2021 Earnings Conference Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
GeoVax Announces $10 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K